Cytopia, YM BioSciences deal

Cytopia's lead candidate is CYT997, a small molecule tubulin inhibitor and vascular targeting agent that is in Phase II trials to treat glioblastoma multiforme (GBM) and relapsed or refractory multiple myeloma (MM). The deal also gives YM BioSciences Cytopia's CYT387, a Janus kinase-2 (JAK-2) inhibitor that will begin a Phase I/II trial to treat myeloproliferative disorders (MPD) in 4Q09. ...